COVID-19 Linked to Heart Inflammation in College Athletes

A small but significant percentage of college athletes with COVID-19 develop myocarditis, a potentially dangerous inflammation of the heart muscle, that can only be seen on cardiac MRI, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

Myocarditis, which typically occurs as a result of a bacterial or viral infection, can affect the heart’s rhythm and ability to pump and often leaves behind lasting damage in the form of scarring to the heart muscle. It has been linked to as many as 20% of sudden deaths in young athletes. The COVID-19 pandemic raised concerns over an increased incidence of the condition in student-athletes.

For the new study, clinicians at schools in the highly competitive Big Ten athletic conference collaborated to collect data on the frequency of myocarditis in student-athletes recovering from COVID-19 infection. Conference officials had required all athletes who had COVID-19 to get a series of cardiac tests before returning to play, providing a unique opportunity for researchers to collect data on the athletes’ cardiac status.

Jean Jeudy, M.D., professor and radiologist at the University of Maryland School of Medicine in Baltimore, serves as the cardiac MRI core leader for the Big Ten Cardiac Registry. This registry oversaw the collection of all the data from the individual schools of the Big Ten conference.

Dr. Jeudy reviewed the results of 1,597 cardiac MRI exams collected at the 13 participating schools. There was no selection bias for cardiac MRI, as all COVID-positive athletes underwent a complete cardiac battery of tests including cardiac MRI, echocardiogram, ECG and blood tests, as well as a complete medical history.

Thirty-seven of the athletes, or 2.3%, were diagnosed with COVID-19 myocarditis, a percentage on par with the incidence of myocarditis in the general population. However, an alarmingly high proportion of the myocarditis cases were found in athletes with no clinical symptoms. Twenty of the patients with COVID-19 myocarditis (54%) had neither cardiac symptoms nor cardiac testing abnormalities. Only cardiac MRI identified the problem.

“Testing patients for clinical symptoms of myocarditis only captured a small percentage of all patients who had myocardial inflammation,” Dr. Jeudy said. “Cardiac MRI for all athletes yielded a 7.4-fold increase in detection.”

The implications of post-COVID-19 myocardial injury detected by cardiac MRI are still unknown.

“The main issue is the presence of persistent inflammation and/or myocardial scar,” Dr. Jeudy said. “Each of these can be an underlying foundation for additional damage and increased risk of arrhythmia.”

As part of the study, Dr. Jeudy and colleagues continue to add to the Big Ten Cardiac Registry to gain more understanding.

“We still don’t know the long-term effects,” Dr. Jeudy said. “Some athletes had issues that resolved within a month, but we also have athletes with continued abnormalities on their MRI as a result of their initial injury and scarring. There are a lot of chronic issues with COVID-19 that we need to know more about, and hopefully this registry can be one of the major parts of getting that information.”

The registry will allow researchers to look beyond the presence of abnormalities and study things like changes in exercise function over time.

“These are young patients, and the effects of myocardial inflammation can potentially impact their lives more significantly than in older patients,” Dr. Jeudy said. “That’s why we really want to push forward and continue to collect this data.”

Obstacles to widespread use of cardiac MRI in college athletes are significant and include cost and lack of access to advanced MRI capability at many centers. But, as the new study shows, cardiac MRI adds considerable value to cardiac testing.

“The role of cardiac MRI as a screening tool in this population needs to be explored,” Dr. Jeudy said. “The reality is that there are a small percentage of cases where we know the athletes have an increased risk for sudden death, and using cardiac MRI will increase the number of players who are identified.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”